| ME0328 |
ME0328 |
1445251-22-8 |
| SAR 131675 |
SAR131675 |
1433953-83-3 |
| GlyT2-IN-1 |
CS-2063 |
448947-81-7 |
| APX-115 freebase |
APX-115 freebase |
1270084-92-8 |
| ethyl 4-(((2R,3R,4S,5R,6S)-4,5-bis(benzo[d][1,3]dioxol-5-ylcarbamoyloxy)-2-(hydroxymethyl)-6-methoxy-tetrahydro-2H-pyran-3-yloxy)carbonyl)benzoate |
BRD7552 |
1137359-47-7 |
| 4-((5'-chloro-2'-((1R,4r)-4-((R)-1-methoxypropan-2-ylamino)cyclohexylamino)-2,4'-bipyridin-6-ylamino)methyl)tetrahydro-2H-pyran-4-carbonitrile |
化合物NVP-2 |
1263373-43-8 |
| 6-(2-Chloro-4-thiazol-5-yl-phenyl)-8-ethyl-2-[4-(4-Methyl-piperazin-1-yl)-phenylaMino]-8H-pyrido[2,3-d]pyriMidin-7-one |
FRAX597 |
1286739-19-2 |
| CP21R7(CP21) |
GSK-3Β抑制剂(CP21R7) |
125314-13-8 |
| AS1842856 |
5-氨基-7-(环己基氨基)-1-乙基-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸 |
836620-48-5 |
| Amg 517 |
N-[4-[[6-[4-(三氟甲基)苯基]-4-嘧啶基]氧基]-2-苯并噻唑基]乙酰胺 |
659730-32-2 |
| 2-Naphthalenecarboxylic acid, 3-hydroxy-, 2-[(2,4,5-trihydroxyphenyl)Methylene]hydrazide |
DYNGO-4A |
1256493-34-1 |
| 7ACC-2 |
7ACC-2 |
1472624-85-3 |
| ALK inhibitor 2 |
2-[[5-氯-2-[[2-甲氧基-4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]氨基]-N-甲基苯磺酰胺 |
761438-38-4 |
| MMP-9-IN-1 |
MMP-9-IN-1 |
502887-71-0 |
| GSK 2830371 |
GSK 2830371 |
1404456-53-6 |
| SR-9243 |
N-[2-(3-溴苯基)乙基]-2,4,6-三甲基-N-[[3'-(甲基磺酰基)[1,1'-联苯]-4-基]甲基]苯磺酰胺 |
1613028-81-1 |
| dolasetron |
多拉司琼 |
115956-12-2 |
| Aftin-4 |
866893-90-5 |
866893-90-5 |
| 6-AMINO-4-(4-PHENOXYPHENYLETHYLAMINO)QUINAZOLINE |
N4-[2-(4-苯氧基苯基)乙基]-4,6-喹唑啉二胺 |
545380-34-5 |
| ADX-47273 |
(S)-(4-氟苯基)-{3-[3-(4-氟苯基)-[1,2,4]二唑-5-基]哌啶-1-基}甲酮 |
851881-60-2 |
